PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease. The collaboration brings together ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience to develop high-quality iPSC-derived motor neuron models that can be used to test therapies, inform clinical trial design, and identify distinct biological subtypes of ALS/MND.

The ALS Therapy Development Institute (ALS TDI) is proud to announce that it will lead all research operations for Champion Insights—a new study planned to launch this fall in partnership with Answer ALS and Augie’s Quest to Cure ALS. This effort aims to uncover critical genetic and metabolic factors that may help explain the significantly higher incidence of amyotrophic lateral sclerosis (ALS) among endurance athletes, military service members, and other potentially high-risk groups.